- Home
- CUE vs ZDAI Comparison
CUE vs ZDAI Comparison
Compare CUE & ZDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | ZDAI |
|---|---|---|
| Founded | 2014 | 2022 |
| Country | United States | Hong Kong |
| Employees | N/A | 33 |
| Industry | Biotechnology: Pharmaceutical Preparations | General Bldg Contractors - Nonresidential Bldgs |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 17.5M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CUE | ZDAI |
|---|---|---|
| Price | $21.68 | $2.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $120.00 | N/A |
| AVG Volume (30 Days) | ★ 965.7K | 80.0K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $0.20 |
| 52 Week High | $41.42 | $11.48 |
Technical Indicators
Market Signals| Indicator | CUE | ZDAI |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 43.86 |
| Support Level | $0.30 | $1.74 |
| Resistance Level | $41.42 | $2.52 |
| Average True Range (ATR) | 4.04 | 0.26 |
| MACD | -1.89 | 0.06 |
| Stochastic Oscillator | 14.17 | 61.47 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About ZDAI Primega Group Holdings Limited Ordinary Shares
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.